APCCC 2024: In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”?
APCCC 2024 metastatic hormone sensitive prostate cancer (mHSPC), patients with mHSPC that should receive “total therapy”, External beam radiation, abiraterone, enzalutamide, apalutamide, darolutamide.